AKBA Akebia Therapeutics Inc

Price (delayed)

$1.13

Market cap

$236.84M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.23

Enterprise value

$232.66M

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is ...

Highlights
AKBA's debt has dropped by 51% year-on-year and by 13% since the previous quarter
Akebia Therapeutics's EPS has increased by 28% YoY and by 18% from the previous quarter
The equity has dropped by 90% year-on-year but it is up by 11% since the previous quarter
The company's gross margin fell by 11% YoY but it rose by 5% QoQ
AKBA's gross profit is down by 38% year-on-year
Akebia Therapeutics's revenue has decreased by 31% YoY and by 3.8% QoQ

Key stats

What are the main financial stats of AKBA
Market
Shares outstanding
209.6M
Market cap
$236.84M
Enterprise value
$232.66M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.24
EV/EBIT
N/A
EV/EBITDA
31.69
EV/Sales
1.24
Earnings
Revenue
$187.23M
EBIT
-$36.06M
EBITDA
$7.34M
Free cash flow
-$25.28M
Per share
EPS
-$0.23
Free cash flow per share
-$0.12
Book value per share
-$0.13
Revenue per share
$0.91
TBVPS
$0.68
Balance sheet
Total assets
$225.48M
Total liabilities
$252.74M
Debt
$37.78M
Equity
-$27.26M
Working capital
$46.46M
Liquidity
Debt to equity
-1.39
Current ratio
1.7
Quick ratio
1.03
Net debt/EBITDA
-0.57
Margins
EBITDA margin
3.9%
Gross margin
65%
Net margin
-23%
Operating margin
-16.9%
Efficiency
Return on assets
-18%
Return on equity
N/A
Return on invested capital
-64.8%
Return on capital employed
-22.7%
Return on sales
-19.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AKBA stock price

How has the Akebia Therapeutics stock price performed over time
Intraday
-1.74%
1 week
-8.13%
1 month
-16.91%
1 year
-2.59%
YTD
-8.87%
QTD
-38.25%

Financial performance

How have Akebia Therapeutics's revenue and profit performed over time
Revenue
$187.23M
Gross profit
$121.66M
Operating income
-$31.65M
Net income
-$43.03M
Gross margin
65%
Net margin
-23%
AKBA's gross profit is down by 38% year-on-year
Akebia Therapeutics's revenue has decreased by 31% YoY and by 3.8% QoQ
The operating income is up by 26% year-on-year and by 26% since the previous quarter
AKBA's net income is up by 25% YoY and by 17% from the previous quarter

Growth

What is Akebia Therapeutics's growth rate over time

Valuation

What is Akebia Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.24
EV/EBIT
N/A
EV/EBITDA
31.69
EV/Sales
1.24
Akebia Therapeutics's EPS has increased by 28% YoY and by 18% from the previous quarter
The equity has dropped by 90% year-on-year but it is up by 11% since the previous quarter
Akebia Therapeutics's revenue has decreased by 31% YoY and by 3.8% QoQ
The price to sales (P/S) is 23% less than the 5-year quarterly average of 1.6 and 4.6% less than the last 4 quarters average of 1.3

Efficiency

How efficient is Akebia Therapeutics business performance
The return on invested capital has declined by 39% year-on-year but it is up by 12% since the previous quarter
The ROA has contracted by 24% YoY but it has grown by 13% from the previous quarter
Akebia Therapeutics's ROS has increased by 18% from the previous quarter but it has decreased by 15% YoY

Dividends

What is AKBA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKBA.

Financial health

How did Akebia Therapeutics financials performed over time
AKBA's total assets is 11% smaller than its total liabilities
Akebia Therapeutics's current ratio has increased by 44% QoQ and by 16% YoY
The company's quick ratio rose by 26% QoQ and by 14% YoY
The equity has dropped by 90% year-on-year but it is up by 11% since the previous quarter
The debt to equity has surged by 74% year-on-year and by 2.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.